SCHEMBL1336852

SCHEMBL1336852

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4nc(CN)cs4)ccc3n(C)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHMT1 P34896 6/20 0.38
▸ SHMT2 P34897 4/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ EIF4E P06730 1/20 0.37
▸ CNR1 P21554 3/20 0.36
▸ CNR2 P34972 3/20 0.36
▸ DPP4 P27487 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ CRHBP P24387 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ CRHR2 Q13324 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338957 0.92 GFER (0.44) SHMT1SHMT2LMNARXFP1L3MBTL1
SCHEMBL1338217 0.91 SHMT1 (0.40) SHMT1SHMT2LMNARXFP1L3MBTL1
SCHEMBL1338195 0.90 SHMT1 (0.37) SHMT1SHMT2LMNARXFP1L3MBTL1
SCHEMBL1339424 0.90 SHMT1 (0.47) SHMT1SHMT2LMNAEIF4ECNR1
SCHEMBL1338076 0.88 CNR1 (0.40) EIF4ECNR1CNR2DPP4KDM4E
SCHEMBL1338722 0.88 GABRA1 (0.42) SHMT1SHMT2LMNARXFP1L3MBTL1
SCHEMBL1338262 0.88 ENPP2 (0.46) ADORA2AADORA1MAOB
SCHEMBL1339227 0.87 GABRA1 (0.41) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL1338822 0.84 PARP1 (0.37) LMNAEIF4ECNR1CNR2DPP4
SCHEMBL1339064 0.83 SREBF2 (0.38) LMNARXFP1L3MBTL1DPP4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US claimed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP claimed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US claimed
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 SHMT1 1498/4885SHMT2 467/4885LMNA 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback